October 20th, 2014 |
14:00 |
IMI Round Table (by invitation)
|
19:00 |
VIP Dinner (by invitation)
|
October October 21st, 2014, London – Royal College of Physicians |
8:30 |
Registration
|
9:00 |
Introduction, Sir Richard Thompson, Immediate Past President, Royal College of Physicians
|
9:05 |
New Pathways for Development and Better Patient Outcomes
- George Freeman, Parliamentary Under Secretary of State for Life Sciences, UK Government
- Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency
- Paolo Daniele Siviero, Head of Pharmaceutical Policy, Italian Medicines Agency
- Stephen Whitehead, Chief Executive, ABPI
- Michel Goldman, Executive Director, IMI
- Andrew Ward, Pharmaceutical correspondent, Financial Times (Moderator)
|
10:30 |
Coffee
|
10:50 |
New Pathways & New Sources of Evidence. What do we need?
- Marc Trusheim, MIT Sloan School of Management
- Finn Børlum Kristensen, Executive Director, Eunetha
- Jillian Oderkirk, Senior Analyst, Health Division, OECD
- Olga Solomon, Deputy Head of Unit, European Commission
- Richard Torbett, Chief Economist, EFPIA
- Helmut Brand, Jean Monnet Professor of European Public Health, Maastricht University (Moderator)
|
12:10 |
Lunch & networking |
13:00 |
High Quality Patient Data and MAPPs; Better Patient Outcomes, Faster and Cheaper
- Duane Schulthess, Managing Director, Vital Transformation
- Mohammad Al-Ubaydli, CEO, Patients Know Best
- Joel Haspel, Director Strategy & Business Development EMEA, Oracle Health Sciences
- Adam Heathfield, Senior Director Global Health and Value Innovation Center, Pfizer
- Tim Williams, Head of Research, Clinical Practice Research Datalink, MHRA
- Wendy Currie, Editor, Health Policy and Technology (Moderator)
|
Blazing Trails – New Development Pathways in Action
- Sandrine Marreaud, Head of Medical and Pharmacovigilance Department, EORTC
- Ryan Hohman, Managing Director, Friends of Cancer Research
- Laura Esserman, Breast Cancer Center Director (I-Spy), University of California San Francisco
- James Anderson, Director of EU Industry & External Partnerships, GSK
- Edward Abrahams, President, Personalized Medicine Coalition (Moderator)
|
14:20 |
Coffee
|
14:40 |
Real World Evidence – What works?
- Ifty Ahmed, CEO, Pow Health
- Jack Bowman, CEO, Handle My Health
- John Crawford, Healthcare Industry Leader, IBM Europe
- Bart Vannieuwenhuyse, Senior Director Health Information Sciences, Janssen Pharmaceutical Companies of Johnson and Johnson
- Geoff Wilson, HTA Task Force Leader, COCIR
- Gary Finnegan (Moderator)
|
The Patient’s Understanding of Benefit Risk
- Pat Furlong, CEO, Parent Project Muscular Dystrophy
- Yann Le Cam, CEO, Eurordis
- Sarah Garner, National Institutes of Clinical Excellence
- Andrea Beyer, Expert Benefit Risk Assessment
- Bettina Ryll, Founder, Melanoma Patient Network Europe
- Alastair Kent, Director, Genetic Alliance UK (Moderator)
|
15.50 |
Break
|
16:00 |
Wrap-up from workshop sessions
|
16:10 |
IMI2: Putting MAPPs Into Practice in Europe
- Nathalie Seigneuret, Senior Scientific Project Manager, IMI
- Dr Cornelius Schmaltz, Deputy Head of Unit of the Fighting Infectious Diseases and Global Epidemics unit, European Commission
- Richard Barker, Director, CASMI
- Jeremy Haigh, European Chief Operating Officer, Research & Development, Amgen Ltd.
- Faraz Kermani, Senior Editor Europe, The Pink Sheet (Moderator)
|
17:15 |
Cocktail Reception
|